Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with Pseudomonas aeruginosa Pneumonia
Authors:
- Adaia Albasanz-PuigAAAdaia Albasanz-Puig
- Xavier Durà-MirallesXDXavier Durà-Miralles
- Júlia Laporte-AmargósJLJúlia Laporte-Amargós
- Alberto MussettiAMAlberto Mussetti
- Isabel Ruiz-CampsIRIsabel Ruiz-Camps
- Pedro Puerta-AlcaldePPPedro Puerta-Alcalde
- Edson AbdalaEAEdson Abdala
- Chiara OltoliniCOChiara Oltolini
- Murat AkovaMAMurat Akova
- José Miguel MontejoJMJosé Miguel Montejo
- Malgorzata MikulskaMMMalgorzata Mikulska
- Pilar Martín-DávilaPMPilar Martín-Dávila
Open Access
- 29 March 2022
- journal article
- research article
- Published by MDPI AG in Microorganisms
- Vol. 10 (4) , 733
Abstract
To assess the effect of combination antibiotic empirical therapy on 30-day case-fatality rate in neutropenic cancer patients with Pseudomonas aeruginosa (PA) bacteremic pneumonia. This was a multinational, retrospective cohort study of neutropenic onco-hematological patients with PA bloodstream infection (BSI) (2006–2018). The effect of appropriate empirical combination therapy, appropriate monotherapy and inappropriate empirical antibiotic therapy [IEAT] on 30-day case-fatality was assessed only in patients with PA bacteremic pneumonia. Among 1017 PA BSI episodes, pneumonia was the source of BSI in 294 (28.9%). Among those, 52 (17.7%) were caused by a multidrug-resistant (MDR) strain and 68 (23.1%) received IEAT, mainly when the infection was caused by an MDR strain [38/52 (73.1%) vs. 30/242 (12.4%); p < 0.001]. The 30-day case-fatality rate was higher in patients with PA bacteremic pneumonia than in those with PA BSI from other sources (55.1% vs. 31.4%; p < 0.001). IEAT was associated with increased 30-day case-fatality (aHR 1.44 [95%CI 1.01–2.03]; p = 0.042), whereas the use of appropriate combination empirical treatment was independently associated with improved survival (aHR 0.46 [95%CI 0.27–0.78]; p = 0.004). Appropriate empirical monotherapy was not associated with improved overall survival (aHR 1.25 [95%CI 0.76–2.05]; p = 0.39). Combination antibiotic empirical therapy should be administered promptly in febrile neutropenic patients with suspected pneumonia as the source of infection.Keywords
Funding Information
- Instituto de Salud Carlos III (CB21/13/00009, CB21/13/00079, CB21/13/00054, CB21/13/00086, CB21/13/00012)
This publication has 45 references indexed in Scilit:
- Clinical and microbiological characteristics of tigecycline non-susceptible Klebsiella pneumoniaebacteremia in TaiwanBMC Infectious Diseases, 2014
- Risk factors, clinical features, and outcome of Pseudomonas aeruginosa bacteremia in patients with hematologic malignancies: A case-control studyAmerican Journal of Infection Control, 2013
- Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosapneumoniaBMC Infectious Diseases, 2012
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistanceClinical Microbiology and Infection, 2012
- High content live cell imaging for the discovery of new antimalarial marine natural productsBMC Infectious Diseases, 2012
- Pneumonia in allogeneic stem cell transplantation recipients: a multicenter prospective studyClinical Transplantation, 2011
- Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2011
- Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignanciesHaematologica, 2010
- Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infectionInternational Journal of Infectious Diseases, 2010
- Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studiesBMJ, 2007